KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Debt Repayments (2016 - 2024)

Pacira BioSciences has reported Long-Term Debt Repayments over the past 8 years, most recently at $182.4 million for Q4 2024.

  • Quarterly results put Long-Term Debt Repayments at $182.4 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Sep 2024 was -$182.4 million (down 611.52% YoY), and the annual figure for FY2024 was $191.0 million, changed.
  • Long-Term Debt Repayments for Q4 2024 was $182.4 million at Pacira BioSciences, up from -$182.4 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for PCRX hit a ceiling of $192.6 million in Q1 2022 and a floor of -$182.4 million in Q3 2024.
  • Median Long-Term Debt Repayments over the past 3 years was $35.6 million (2022), compared with a mean of $27.5 million.
  • Peak annual rise in Long-Term Debt Repayments hit 52405.62% in 2020, while the deepest fall reached 52405.62% in 2020.
  • Pacira BioSciences' Long-Term Debt Repayments stood at -$176.8 million in 2020, then surged by 120.16% to $35.6 million in 2022, then soared by 411.52% to $182.4 million in 2024.
  • The last three reported values for Long-Term Debt Repayments were $182.4 million (Q4 2024), -$182.4 million (Q3 2024), and $35.6 million (Q4 2022) per Business Quant data.